close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

78.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Third Quarter 2021 Results
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Second Quarter 2021 Results
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
From ANI Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today